As of Q3'25, CB's latest reported SG&A Expenses stand at 1.138B USD, while R&D Expenses remain at 0 USD. This marks a continued absence of R&D spending and a steady increase in SG&A Expenses over the most recent quarters. From Q1'23 to Q3'25, the chart reveals a consistent trend of zero R&D Expenses, indicating no allocation to research and development throughout the period. SG&A Expenses, on the other hand, have shown a gradual upward trajectory, rising from 930M USD in Q1'23 to 1.138B USD in Q3'25, with only minor fluctuations. The data highlights a stable cost structure focused exclusively on SG&A, with no investment in R&D activities over the observed timeframe.